Italia markets close in 5 hours 50 minutes

Mineralys Therapeutics, Inc. (MLYS)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
12,17-0,46 (-3,64%)
Alla chiusura: 04:00PM EDT
12,17 0,00 (0,00%)
Dopo ore: 04:01PM EDT
Schermo intero
Caricamento grafico interattivo in corso...
  • GlobeNewswire

    Mineralys Therapeutics Announces Upcoming Poster Presentations at Two Scientific Conferences in November 2023

    Late-breaking poster presentation at ASN’s Kidney Week 2023 - - -Poster presentation at AHA’s Scientific Sessions 2023 RADNOR, Pa., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced upcoming poster presentations at two scientific conferences being held in November

  • GlobeNewswire

    Praxis Bioresearch Expands its Board of Directors with Appointment of Adam Levy

    Adam Levy Appointment to Board of Directors LOS ANGELES, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Praxis Bioresearch (“Praxis”), a biopharmaceutical company focused on the discovery and development of therapeutics for chronic neuropsychiatric and neurodegenerative disorders with an initial focus on apathy in Alzheimer’s Disease, today announced the appointment of Adam Levy to its Board of Directors (the “Board”). Mr. Levy brings executive, financial and operational leadership experience in biopharmace

  • GlobeNewswire

    Mineralys Therapeutics Expands its Board of Directors with Appointments of Glenn Sblendorio and Daphne Karydas

    Daphne Karydas Daphne Karydas Glenn Sblendorio Glenn Sblendorio RADNOR, Pa., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced the appointments of Daphne Karydas and Glenn Sblendorio to its Board of Directors (the Board). Ms. Karydas and Mr. Sblendorio bring execu